Talk/Panel - Application of a Specific Theory
Channel: paloaltoinstitute
Date: 2012-06-15

Inducing Adaptation
Joon Yun, M.D.
Palo Alto Investors, Palo Alto Institute

Joon Yun is a partner and the president of Palo Alto Investors. Dr. Yun joined Palo Alto Investors in 1998 and specializes in the healthcare sector. Dr. Yun brings clinical expertise as well as medical industry experience to Palo Alto Investors where he focuses primarily on the evaluation of pharmaceutical, medical device and biotechnology companies.

Dr. Yun was a physician at Stanford in the Department of Radiology where he served on the clinical faculty from 1995 to 2006. Dr. Yun received his bachelor of arts in biology from Harvard University and his doctor of medicine from Duke University School of Medicine.Dr. Yun is one of the founders of Palo Alto Institute and authors many of its publications.

Raymond P. Onders, M.D. 
Synapse Biomedical

Dr. Onders became the first director of minimally invasive surgery at University Hospitals Case Medical Center and associate professor of surgery at Case Western Reserve University School of Medicine. Over the past 12 years, he has focused his research on ways to help people breathe naturally using their own diaphragm. His advancements in the technology of pacing a diaphragm have lead to numerous patents. He is also co-founder of Synapse Biomedical, which is helping to bring his technology to patients all over the globe.


Lorenzo DiCarlo, M.D. 
Proteus Biomedical

Lorenzo DiCarlo is currently Vice President for Global Clinical Affairs focusing on the development of wireless medical, health and wellness products at Proteus Biomedical. Previously he was Director of Medical Sciences and New Technologies for device-based therapies at Guidant Corporation, and Senior Director of Clinical Development at Pfizer Global Research and Development where he was responsible for early and late-stage drug development. 


Richard A. Bond, Ph.D.
University of Houston

Dr. Bond's work has been published in top scientific journals such as Nature, Science, and PNAS, and his work has been featured in numerous editorials and commentaries written by other scientists. His early work provided functional evidence for a β-adrenoceptor that was eventually found to be the β3-adrenoceptor. He is currently Professor of Pharmacology at the University of Houston in Texas.

Kari Nadeau, Ph.D.
Stanford University

Dr. Kari Nadeau is an associate professor of pediatrics (immunology and allergy) and otolaryngology (head and neck surgery) and faculty member of the Institute of Infectious Disease, Transplantation and Immunology. She is a fellow of the American Academy of Asthma, Allergy, and Immunology and was the recipient of the EPA STAR grant, Clinical Immunological Society Faculty Award, the American Lung Association National Faculty Award, and the American Academy of Allergy, Asthma, and Immunology National Faculty Award.